20 results about "Nitrosamine" patented technology

This invention discloses a strain of *Lactobacillus rhamnosus* H7 and its applications, belonging to the field of food microbiology technology. This invention provides a *Lactobacillus rhamnosus* H7 isolated from fermented meat, deposited at the Guangdong Provincial Microbial Culture Collection Center. This strain has the function of degrading nitrite. When inoculated into dried sausage, the residual nitrite and nitrosamine levels in the dried sausage are reduced, and the color of the meat product is significantly improved. When inoculated into fermented mandarin fish, the residual nitrite and nitrosamine levels in the fermented mandarin fish are also reduced. Therefore, inoculating fermented meat products with *Lactobacillus rhamnosus* H7 not only helps improve the safety of fermented meat products but also enhances their quality. This strain has good application prospects as a starter culture for fermented meat products.

This invention discloses a method for the deamination functionalization of aliphatic nitrosamines, comprising: reacting an aliphatic nitrosamine as shown in formula (II) with a nucleophile in the presence of an acid and a solvent to generate a deamination functionalized product as shown in formula (III); wherein, R 1 R 2 R 3 Each group is independently selected from hydrogen, hydroxyl, alkyl, alkoxy, alkanoyl, alkoxycarbonyl, alkylsulfinyl, alkylsulfonyl, aryl, heteroaryl, phenylalkyl, or R 1 R 2 R 3 Two or three of the functional groups form a non-aromatic ring, cage-like compound; FG is a functional group in which a nucleophile participates in the reaction. The method of this invention has the advantages of inexpensive and readily available raw materials, simple reaction conditions, and wide substrate applicability.

This application discloses an analytical method for N-nitrosamine vortioxetine in vortioxetine hydrobromide tablets, belonging to the field of pharmaceutical impurity analysis. The method employs high-performance liquid chromatography (HPLC), with the following chromatographic conditions: a 4.6 mm × 250 mm column packed with octadecylsilane-bonded silica gel, with a particle size of 5 μm; mobile phase A is a 90:10 water-acetonitrile mixture containing 0.025%–0.035% trifluoroacetic acid (v / v); mobile phase B is acetonitrile; gradient elution; column temperature 38–42 °C; flow rate 0.9–1.1 ml / min; injection volume 50 μl; and detection wavelength 226 nm. This analytical method effectively eliminates excipient interference and exhibits excellent detection performance (specificity, sensitivity, linearity, precision, accuracy, and robustness), accurately detecting the content of N-nitrosamine vortioxetine in vortioxetine hydrobromide tablets, meeting quality control requirements.

The present invention provides an oral composition comprising an Lp(a) inhibitor compound having a reduced level of nitrosamine. [Solution] An oral composition comprising muvalaprin and histidine is used, wherein novel polymorphs of muvalaprin, such as muvalaprin hydrate form A, muvalaprin hydrate form B, muvalaprin hemihydrate, and muvalaprin hydrate 1:6.5 molar equivalents, muvalaprin hemihydrate and / or muvalaprin hydrate 1:6.5 molar equivalents are used. Furthermore, the composition provides a method for treating cardiovascular disease, a method for treating atherosclerotic cardiovascular disease, and / or a method for lowering Lp(a) levels in an individual by administering one of the oral compositions.

This invention relates to the field of pharmaceutical technology, specifically proposing the application of ligustilide in the preparation of drugs for inhibiting and / or preventing and / or alleviating and / or treating lung tumors to address the current lack of natural drugs for lung cancer prevention. Lung tumors are nitrosamine-induced carcinogenesis of lung tissue. The invention relates to a pharmaceutical preparation for inhibiting and / or preventing and / or alleviating and / or treating lung tumors, comprising an active ingredient and pharmaceutically acceptable excipients; wherein the active ingredient is ligustilide. Ligustilide directly targets the STING protein, activates the cGAS-STING pathway, promotes STING phosphorylation and cell-mediated immune surveillance, while simultaneously regulating ROS homeostasis and the inflammatory microenvironment, reducing nitrosamine damage to lung epithelial cells, and preventing nitrosamine-induced lung carcinogenesis.

The application provides a pharmaceutical composition of venlafaxine hydrochloride, which comprises a pill core, a quick-release layer and a slow-release layer, and optionally further comprises an isolation layer and / or a protective layer, wherein the quick-release layer contains an antioxidant. The pharmaceutical composition provided by the application has good stability, can effectively inhibit the growth of nitrosamine impurities in the process of preparation and the process of storage of the preparation, has little influence on related substances, has good storage stability of the product, and has beneficial effects such as similar dissolution of the preparation to a reference preparation. The application further provides a preparation method of the pharmaceutical composition, which is simple in operation and suitable for industrial application.

This invention provides a stable sitagliptin phosphate pharmaceutical composition comprising the following components: the active ingredient sitagliptin phosphate, a sulfite stabilizer, a filler, a disintegrant, and a lubricant. By adding a sulfite stabilizer to the sitagliptin phosphate pharmaceutical composition, this invention effectively controls the formation of nitrosamine impurities (NTTP) in the sitagliptin pharmaceutical composition, ensuring the quality stability of the sitagliptin phosphate pharmaceutical composition. The sitagliptin phosphate pharmaceutical composition of this invention has a dissolution effect comparable to a reference. The stable sitagliptin phosphate pharmaceutical composition of this invention is prepared using conventional preparation processes and is suitable for industrial production.

The application discloses an organic boron reagent alpha-boryl oxime compound and a preparation method and application thereof, and belongs to the technical field of organic synthesis. N The alpha-boryl oxime compound is prepared by reacting a heterocyclic carbene borane adduct and a nitroso compound in an organic solvent. N The alpha-boryl oxime compound is prepared by simultaneously introducing an oxime group and a boron group functional group into both ends of the olefin with high selectivity through the boro-oximation reaction of the heterocyclic carbene borane, the nitrosamine compound and the olefin. The reaction avoids the use of a photosensitizer and a transition metal, has very good functional group tolerance and substrate universality, and also has good chemical selectivity, regioselectivity and stereoselectivity; the product alpha-boryl oxime compound can be efficiently used to synthesize various useful compounds through simple conversion, the types of the organic boron reagent are expanded, and the application prospect is good.

This invention discloses a strain of *Lactobacillus brevis* and its applications, belonging to the field of food microbiology technology. The invention provides a strain of *Lactobacillus brevis* CHOL1, isolated from sauerkraut. After safety evaluation, this strain is suitable for use in food. It exhibits a strong ability to degrade nitrite and can also react with myoglobin to generate nitrosomyoglobin. Inoculation of this strain into fermented meat products revealed that it can reduce nitrite and nitrosamine residues while improving the color of the meat products. As a starter culture, this strain can improve the quality and safety of fermented meat products and can serve as a natural and effective substitute for nitrite in fermented meat products.

The present invention relates to a process for the preparation of benzgalantamine, or a pharmaceutically acceptable salt, or a hydrate thereof. The present invention also relates to benzgalantamine or a pharmaceutically acceptable salt, or a hydrate thereof substantially free of one or more impurities of compounds of Formulae A, B, C, or D as described in the specification. The process of the present invention further provides benzgalantamine or a pharmaceutically acceptable salt, or a hydrate thereof, substantially free of nitrosamine impurities of compounds of Formulae E and F. The present invention also provides a crystalline form of benzgalantamine and a process for the preparation thereof.

The present invention relates to stable delayed-release enteric-coated pharmaceutical compositions comprising duloxetine hydrochloride which are composed of a pellet core and multiple coating layers such as drug layer, separating layer and enteric layer presenting suitable in-vitro release and nitrosamine impurity profile.

This invention relates to N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide drug substance substantially free of a nitrosamine impurity, e.g. the nitrosamine impurity N-(3-(6-amino-5-(2(methyl)(nitroso)amino)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide and novel processes of preparation thereof. The invention further relates to pharmaceutical composition comprising N-(3-(6-Amino-5-(2-(N- methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, wherein the composition is substantially free of a nitrosamine impurity, e.g. the nitrosamine impurity N-(3-(6-amino-5-(2(methyl)(nitroso)amino)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide. Pharmaceutical products containing said drug substance and compositions are also disclosed, as well as methods for preparing said drug substance, pharmaceutical compositions and products.

The present invention relates to a solid oral pharmaceutical composition that includes: (a) an active pharmaceutical ingredient; (b) a nitrosamine inhibitor that includes linear or branched C1-C10 alkyl 3,4,5-trihydroxybenzoate; and (c) a pharmaceutically acceptable excipient. At least one of: (i) the active pharmaceutical ingredient includes at least one covalently bonded amine group that is subject to conversion to nitrosamine; or (ii) the solid oral pharmaceutical composition includes at least one amine, that is other than the amine group covalently bonded to / within the active pharmaceutical ingredient, and which is subject to conversion to nitrosamine. The nitrosamine inhibitor is present in an amount at least sufficient to reduce the amount of nitrosamine formed in the solid oral pharmaceutical composition, compared to the amount of nitrosamine formed in a comparative solid oral pharmaceutical composition that is free of the nitrosamine inhibitor.

With the expansion of nuclear energy utilization, the safe disposal and reuse of the large amounts of depleted uranium produced after nuclear enrichment has become an urgent issue in pollution prevention and control. This invention aims to explore a method for the safe disposal and reuse of depleted uranium (…). 238 A new model for utilizing uranium (which poses no radioactive harm to humans) specifically involves using U3O8, obtained from depleted UF6, as a raw material to prepare α-UO3 via a simple dissolution-reprecipitation method. Using α-UO3 as a catalyst, an organic solvent as the reaction solvent, and hydrogen peroxide as the oxidant, aniline or its derivatives can be selectively oxidized to nitrosamine or its derivatives. This invention innovatively solves the problem of reusing depleted uranium waste, providing a new approach to nuclear waste treatment. Furthermore, by converting aniline and its derivatives into higher value-added nitrosamine or its derivatives, it maximizes resource utilization. Whether from the perspective of environmental protection and sustainable development, or from the perspective of increasing the added value of the product, this invention has extremely important value and far-reaching significance.

This invention provides a stable solid pharmaceutical composition comprising at least one of vortioxetine or a pharmaceutically acceptable salt thereof, an antioxidant, and / or a basic agent, optionally further comprising one or more pharmaceutically acceptable excipients. The pharmaceutical composition provided by this invention effectively inhibits the increase of nitrosamine impurities in solid dosage forms during storage, while also exhibiting advantages such as minimal impact on related substances, good product storage stability, and similar dissolution characteristics to the reference formulation. This invention also provides a method for preparing the solid dosage form, which is simple to operate and suitable for industrial application.

The application discloses a kind of detection methods of N-dimethyl nitrosamine in meat product, comprising: step one, cut piece of meat product, put into soaking liquid and soak, ultrasonic oscillation, clean with clean water;Step two, the meat block is crushed, add acetonitrile, anhydrous magnesium sulfate, n-hexane, drop 0.1% glacial acetic acid, ultrasonic oscillation, stand, liquid separation, take acetonitrile layer, repeat 1-3 times, combine acetonitrile layer, add extractant again, ultrasonic oscillation, centrifugal, obtain filtrate;Step three, take solid-phase extraction column activation, sample filter liquor, elution, nitrogen blowing, redissolve, filter, obtain sample to be measured;Step four, the sample to be measured is carried out qualitative and quantitative detection using gas chromatography mass spectrometry, and the content of N-dimethyl nitrosamine is obtained.The application detects N-dimethyl nitrosamine by removing grease and residual components after pretreatment of meat product, with high accuracy and precision.

This invention discloses a Cherry Valley duck hepatoma cell line (DMH) and its applications. It relates to the field of biotechnology. It provides a method for establishing immortalized duck hepatoma cells and related applications. This invention has good market demand and application value. It provides stable cell material for scientific research on duck viral hepatitis virus and the development and production of vaccines. Based on a duck hepatoma model induced by diethylnitrosamine (DEN), this invention obtains a highly active and pure duck hepatoma cell line through standardized primary tumor cell isolation, culture, and identification procedures. This cell line can efficiently support the proliferation of waterfowl hepatotropic viruses, and is particularly suitable for the culture of duck viral hepatitis virus, providing an ideal cell carrier for waterfowl viral pathogen research and vaccine development.

The application belongs to the technical field of herbicide purification, and particularly relates to a continuous washing process of low nitrosamine trifluralin. The washing process comprises the following steps: S1: mixing hydrochloric acid with a bromide salt nucleophilic catalyst and sulfamic acid to obtain a catalytic acid phase; S2: pumping the crude trifluralin and the catalytic acid phase into a static mixer for mixing, and then pumping the mixture into an automatic phase separator to obtain acid-washed crude products and separated catalytic acid phase; S3: pumping the acid-washed crude products and water into a static mixer for mixing and phase separation to obtain wet trifluralin products; and performing post-treatment on the wet trifluralin products to obtain low nitrosamine trifluralin. The application utilizes nucleophilic catalysis to enhance the nitrosamine degradation efficiency, and simultaneously removes nitrous acid active intermediates through sulfamic acid, so that the content of nitrosamine in trifluralin can be less than or equal to 1.0 ppm under mild conditions.